Windlas Biotech Ltd

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests increasing caution for investors amid a challenging market backdrop.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Windlas Biotech Ltd recorded a robust intraday performance on 14 Jan 2026, surging 7.03% to touch a day’s high of Rs 867, significantly outperforming the Pharmaceuticals & Biotechnology sector and broader market indices.

Windlas Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 11 January 2026, providing investors with an up-to-date view of the company's performance and outlook.

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Windlas Biotech has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by a combination of financial trends, valuation considerations, and technical indicators. This development comes amid a challenging year for the small-cap pharmaceutical and biotechnology company, which has seen its stock performance diverge notably from broader market indices.

Windlas Biotech has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters amid a backdrop of subdued stock performance and sector challenges. This adjustment highlights evolving perspectives on the company’s financial health, valuation, and technical outlook within the Pharmaceuticals & Biotechnology sector.

Windlas Biotech, a small-cap pharmaceutical company, has faced a challenging year with a return of -16.53%, contrasting with the Sensex's gain. Technical indicators suggest a bearish sentiment, yet the company has shown resilience with a notable 247.73% return over the past three years, outperforming the Sensex significantly.

Windlas Biotech has recently encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has declined 0.51%, contributing to a one-year performance of -16.53%, while its market capitalization is Rs 1,779.00 crore, with a P/E ratio lower than the industry average.

Windlas Biotech has faced a notable decline, losing 7.35% on November 7, 2025. The stock has underperformed the sector and broader market trends, trading below key moving averages. Year-to-date, it has decreased by 14.96%, contrasting sharply with the Sensex's gain of 6.46%.

Windlas Biotech, a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a shift in its technical indicators, moving to a mildly bearish trend. Despite a positive quarterly financial performance, the stock has underperformed compared to the broader market over the past year.

Windlas Biotech, a small-cap pharmaceutical company, has experienced a challenging year with a return of -17.01%, contrasting with the Sensex's modest gain. Despite recent fluctuations, the company has shown resilience with a significant 284.38% return over the past three years, outperforming the Sensex during that period.

Windlas Biotech Ltd., a contract development and manufacturing organisation (CDMO) in the pharmaceutical sector, reported a net profit of ₹17.80 crores for Q2 FY26, marking a modest sequential increase of 0.79% from ₹17.66 crores in Q1 FY26. On a year-on-year basis, net profit grew 13.67% from ₹15.66 crores in Q2 FY25. With a market capitalisation of ₹1,973 crores and a current price of ₹932.90, the stock has declined 17.01% over the past year, significantly underperforming both the Sensex and its pharmaceutical sector peers.

Windlas Biotech, a small-cap pharmaceutical company, has seen its stock price decline recently, with mixed technical indicators reflecting its market performance. While it has outperformed the Sensex over the past week, longer-term returns show declines year-to-date and over the past year, despite significant growth over three years.